EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

VISION EUROPE 2030

Disruptive Technologies, Democratized Trials & Next-Gen Treatment Paradigms

September 2^{2n} -3rd, 2025

Club University Foundation
11, Rue d'Egmont, 1000 Bruxelles

Setting the Scene: The Urgent Case for a Tech-Driven Revolution

The Innovation Paradox

Across every major disease area—from cancer and cardiovascular disease to neurodegeneration and rare conditions—science is moving faster than systems can absorb. AI-powered diagnostics, liquid biopsy, and decentralized trial models are no longer theoretical—they're clinically validated, scalable, and transformative. Yet health systems remain entrenched in outdated models of care, with regulatory inertia, siloed reimbursement, and geographic inequities delaying access to life-saving innovation.

The result: a growing chasm between what's scientifically possible and what's delivered in practice—costing lives, driving inefficiency, and eroding public trust.

The Global Challenge

Breakthroughs are real, and their potential is measurable:

- **AI-driven diagnostics**: Retinal scans for diabetes, digital voice biomarkers for Parkinson's, and multimodal AI for early detection are exceeding 80% diagnostic accuracy in trials.
- **Minimally invasive monitoring**: Liquid biopsy is now being piloted not only in oncology but also in Alzheimer's and prenatal care.
- **Tumor-agnostic treatments**: New molecular targets are making old trial models obsolete.

Yet fewer than 1 in 5 eligible patients access these innovations due to:

- **Regulatory lag** – Approval frameworks can't match innovation cycles.
- **Geographic inequity** – Rural and under-resourced facilities lack access to advanced diagnostics.
- **Fragmented reimbursement** – Technologies like next-generation sequencing (NGS) are funded for cancer but not for rare diseases or inherited cardiovascular risks.

EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

What's Missing

A 21st-century health architecture that:

- Moves at the **speed of science**
- Delivers **equitably** across diseases and geographies
- Scales **sustainably** for national budgets and healthcare systems

Conference Vision: From Fragmented to Future-Ready

VISION EUROPE 2030 will catalyze a pan-disease shift—moving from reactive, fragmented care to a system that is **precise, proactive, and patient-centered**. Sessions will chart a path to:

1. Scale Disruptive Tools

- **AI diagnostics**: From oncology to cardiology and neurology
- **Liquid biopsy**: From cancer to neurodegeneration and prenatal health
- **Decentralized trials**: From rare cancer pilots to broad chronic disease integration

2. Fix Systemic Bottlenecks

- **Regulatory harmonization**: Align EU/US pathways for cross-disease biomarkers
- **Reimbursement reform**: Move from volume to value (e.g., outcome-based payments for AI in diabetes)
- **Modular data systems**: Ensure interoperability across disease areas

3. Close the Equity Gap

- **Joint procurement**: Multi-disease diagnostic platforms (e.g., NGS for both cancer and inherited cardiomyopathies)
- **Reflex testing mandates**: For high-impact biomarkers like HER2 (cancer) and APOE4 (Alzheimer's)

Who This Is For

The conference convenes those shaping the next chapter of health innovation:

- **Policymakers**: WHO-Europe, EMA, DG SANTE, national ministries
- **Clinicians**: Oncologists, cardiologists, neurologists, and primary care leaders
- **Industry**: Pharma, diagnostics, and digital health leaders with cross-therapeutic portfolios
- **Patients**: Advocacy groups for cancer, rare, chronic, and neurodegenerative diseases
- **Investors**: Public and private funders focused on platform innovation and health equity

EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

DAY 1- September 2nd, 2025.

09.00 – 09.30: Tech for Equity

Setting the Scene: Denis HORGAN, *Executive Director, European Alliance for Personalised Medicine*

Welcome Addresses:

- **Emer Cooke,** *Executive Director, Chair, ICMRA, The European Medicines Agency*
- **Olivér Várhely,** *European Commissioner for Health and Animal Welfare*
- **Natasha Azzopardi Muscat,** *Director Country Health Policies & Systems, World Health Organization*

09.30 – 10.30: Tech for Equity: Catalyzing Innovation in High-Income Cancer Systems

Disruptive diagnostic technologies—circulating tumor DNA (ctDNA), liquid biopsy, and AI-enhanced pathology—are redefining what's clinically possible in cancer care. Yet despite their precision and predictive power, systemic inertia continues to slow their integration into high-income healthcare systems. This session examines how we can shift from innovation at the margins to innovation embedded in the mainstream.

Drawing on real-world examples from across Europe, speakers will explore how emerging tools are reshaping early detection, recurrence monitoring, and diagnostic efficiency.

Topics include:

- **Using ctDNA for measurable residual disease (MRD)** to anticipate relapse before it manifests clinically
- **Replacing invasive procedures with liquid biopsy** at scale, reducing patient burden and time to diagnosis
- **Deploying AI-assisted digital pathology** to expand diagnostic throughput without compromising quality
- **Leveraging value-based reimbursement pilots** in Germany and the Netherlands to align incentives with patient outcomes
- **Advancing joint regulatory and HTA review models** to streamline access without compromising safety
- **Harnessing EU-wide procurement strategies** to reduce cost variation and promote equity

This session is a call to action for policymakers, payers, and providers to break through implementation inertia and redesign healthcare systems that can absorb innovation, scale it efficiently, and deliver it equitably.

Moderator: Jose M. Martin-Moreno, *Professor of Medicine and Public Health , Clinical Hospital & Medical School, University of Valencia*

Setting the Scene:

- **Tilly Metz**, *Member of the European Parliament (Luxembourg), Greens/EFA group and the national party Déi Gréng – Les Verts*
- **Irene Norstedt**, *Director, People Directorate, DG Research & Innovation, European Commission*

Panel:

- **Prof. Ruggero De Maria, MD, PhD**, *President, Italian Alliance Against Cancer (Alleanza Contro il Cancro), Professor of Pathology, Università Cattolica del Sacro Cuore, Rome*
- **Prof. Fabrice André, MD, PhD**, *Director of Research, Gustave Roussy Institute, Paris, Chair, ESMO Translational Research Working Group*
- **Prof. Peter Schirmacher, MD**, *Director of Pathology, University Hospital Heidelberg, Chief Medical Officer, European Association for Cancer Research (EACR)*

10.30– 11.30 Democratizing Trials – The Rome Trial Blueprint for Inclusive Innovation

Clinical research in high-income countries has long been constrained by outdated infrastructures, urban-centric recruitment, and narrow eligibility criteria. The Rome Trial overturned these norms—demonstrating that real-world data integration and decentralized design can dramatically accelerate timelines while expanding access.
This session unpacks the emerging blueprint for trial reform across Europe and other high-income settings. It highlights how technological and structural innovation can unlock a new era of inclusivity, speed, and sustainability in clinical research.

Key focus areas include:

- **AI-powered patient matching** tools implemented in France and Spain that significantly increased participation from rural, older, and minority populations
- **Blockchain-enabled secure data sharing architectures** that ensure GDPR compliance while facilitating seamless cross-border recruitment
- **Sustainable public–private trial hubs** in Northern Europe and Canada that offer replicable models for scaling equitable research access

This discussion will spotlight how trials can evolve from exclusive academic exercises into truly inclusive, distributed platforms that reflect real-world populations—and generate evidence that is more representative, more timely, and more actionable.

Moderator: Antoni Moliner Monseratt, *Vice président - ALAN Vice President of the National Committee of the Rare Diseases Plan of Luxembourg*

Setting the Scene:

- **Prof. Paolo Marchetti, MD**, *Director of Oncology, Policlinico Umberto I, Rome Past President, Italian Association of Medical Oncology (AIOM)*
- **Dr. Marco Marsella**, *Deputy Head of Unit, DG SANTE (Health Systems and Products), European Commission*

Panel:

- **Alejandro Piris,** *Head of the Scientific Coordination/ Management Area at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona*
- **Prof. Joanna Chorostowska-Wynimko, MD, PhD, DSc**, *President-Elect, European Respiratory Society (2024-2025)*
- **Patrice Verpillat,** *Head of Real World Evidence, European Medicines Agency*

11.30– 12.00 Break

12.00 – 13.00: Precision Oncology 2.0 – Rewriting the Rules: From RCT-Centered Models to Innovation-Ready Systems

As oncology advances toward increasingly personalized and tumor-agnostic approaches, high-income health systems must move beyond rigid, randomized controlled trial (RCT)-centric pathways that struggle to keep pace with innovation. This session explores how clinical and regulatory frameworks can evolve to support next-generation precision oncology.

The discussion will highlight transformative practices that are reshaping oncology evidence generation, including:

- **Leveraging real-world data (RWD)** from national registries in the UK and Germany to inform treatment strategies for high-mortality cancers like glioblastoma
- **Mandating universal molecular profiling at diagnosis**, with examples from Sweden and Austria that are embedding genomics into standard-of-care pathways
- **Institutionalizing tumor-agnostic drug development** by prioritizing rare genomic targets such as RET and NTRK—redefining how eligibility, efficacy, and access are determined

This session will offer a forward-looking roadmap for systems to support precision oncology at scale—grounded in data, designed for flexibility, and driven by patient need.

Moderator: Jose M. Martin-Moreno, *Professor of Medicine and Public Health , Clinical Hospital & Medical School, University of Valencia*

Setting the Scene:

- **Vivek Subbiah, MD**, *Chief of Early-Phase Drug Development, Sarrah Cannon Research Institute, USA*

- **Jean-Yves Blay**, *General Director of the Centre Leon Berard, the Comprehensive Cancer Centre of Lyon, France.*

Panel:

- **Neil Bertelsen**, *Chair, Patient and Citizen Involvement in HTA IG, Health Technology Assessment international (HTAi)*
- **Marek Svoboda, PhD**, *Director General of Masaryk Memorial Cancer Institute Board Member of the Mission on Cancer*
- **TBC**

13.00- 14.00 Lunch

14.00 – 15.15. Public–Private Power Plays – Building Sustainable Partnerships for Scalable Impact

In high-income countries, philanthropy alone cannot drive systemic transformation. Lasting impact demands that public goals and private investment operate in strategic alignment—fueling innovation that is both scalable and sustainable.

This session will explore pioneering models where public–private collaboration has redefined what's possible in data infrastructure, genomics, and value-based care.

The session will outline a roadmap for mobilizing capital, aligning incentives, and scaling innovation—without losing sight of public accountability and long-term value.

Moderator: Antoni Moliner Monseratt, *Vice président - ALAN Vice President of the National Committee of the Rare Diseases Plan of Luxembourg*

Setting the Scene:

- **John Longshore,** *Head of Scientific Affairs for Global Oncology Diagnostics, AstraZeneca*
- **Alessandra Moretti,** *MEP, Member, Committee on the Environment, Public Health and Food*

Panel:

- **Synthia**: **Marilena Bicchieri**, *Scientific Coordinator, , GenoMed4All's*
- **BRECISE**: **Xenia Beltrán**, *Head of Big Data at LifeSTech*
- **Joint Cancer Personalised Medicine*:* Marc Van den Bulcke**, *Head of Service, Cancer Centre*
- **SPARC*:* Manuel Ottaviano, Ph.D,** *Associate professor, Researcher, Project Manager, Universidad Politecnica de Madrid**, Spain***

Q&A

15.15- 15.30 Coffee

15.30- 16.30: Spotlight 1: Bridging the Innovation Gap: Precision Cardiology for the Next Decade

Despite transformative advances in oncology, precision cardiology remains underleveraged across high-income countries. As cardiovascular disease continues to be the leading cause of death globally, the integration of disruptive technologies—AI, biomarkers, and digital diagnostics—into cardiology is essential to improve outcomes and optimize system sustainability.

This session will highlight the urgency of bringing cardiovascular innovation up to pace with scientific and digital progress. It will explore how artificial intelligence can enhance diagnostic precision, how biomarker-guided strategies can personalize care pathways, and how scalable platforms can democratize access across diverse healthcare settings.

Expert speakers will discuss road-tested initiatives and emerging models from across Europe that demonstrate the feasibility and clinical value of next-generation tools. The session will also address the barriers that have limited uptake to date—fragmented data infrastructure, regulatory bottlenecks, and misaligned reimbursement—and propose actionable strategies to overcome them.

Ultimately, this session aims to reframe cardiovascular care through the lens of precision health, offering a blueprint for equitable, efficient, and scalable system transformation.

Moderator: Jose M. Martin-Moreno, *Professor of Medicine and Public Health , Clinical Hospital & Medical School, University of Valencia*

Setting the Scene:

- **Romana Jerković,** *Group of the Progressive Alliance of Socialists and Democrats in the European Parliament*

Speakers to be included:

16.30- 17.30: Spotlight 2: Neurology Breakthroughs

Neurology remains one of the most challenging frontiers in precision medicine. With neurodegenerative diseases such as Alzheimer's, Parkinson's, and multiple sclerosis on the rise, early and accurate diagnosis is critical—but traditional clinical pathways are often too slow, subjective, and resource-intensive to meet this challenge.

EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

This session explores the cutting edge of AI and machine learning in neurology, highlighting how advanced algorithms are driving earlier detection, enhancing prognostic accuracy, and supporting more personalized care pathways. From the analysis of multimodal neuroimaging and voice biometrics to the integration of wearable sensors and digital cognitive assessments, new models are achieving diagnostic accuracies exceeding 90% in some settings.

Yet, systemic gaps remain: rare neurological diseases are underrepresented in research, algorithm performance standards are not harmonized, and complex methods such as deep neural networks or gradient boosting remain underutilized in clinical practice. This panel will address these limitations while showcasing real-world applications—from automated ALS progression tracking to AI-assisted differential diagnosis in dementia.

As regulatory agencies and health systems seek to balance innovation with implementation, this session will offer a roadmap for embedding neuro-AI into routine care—one that supports equity, transparency, and robust clinical validation.

Key Question: *How to reconcile RWD with traditional RCTs in neurology?*

Moderator: **Frédéric Destrebecq**, *Executive Director at the European Brain Council*

Setting the Scene:

- **Romana Jerković,** *Group of the Progressive Alliance of Socialists and Democrats in the European Parliament*

Panel:

- **Ulrike Bußhoff** *(DLR Projektträger), Coordinator of the CSA BrainHealth*
- **Alberto Benussi**, *Associate Professor, University of Trieste*
- **Karim Lekadir**, *ICREA Research Professor, University of Barcelona*

Q&A

19.00- 21.30: Speakers Dinner & Reception in the European Parliament: Keep the Person in Personalised HealthCare

- **Dolors Montserrat**, *(Spain, EPP) – ENVI*
- **Tilly Metz**, *(Luxembourg, Greens) – ENVI, SANT*
- **Tomislav Sokol,** *(Croatia, EPP) – EMPL*

Stakeholder speakers:

- **Marzia Zambon,** *Executive Director, Europa Donna*
- **Zorana Maravic,** *CEO, Digestive Cancers Europe*

- **Angeliki Paraskevopoulou-Souri,** *Vice-president, LuCE.*
- **Vivek Subbiah, MD**, *Chief of Early-Phase Drug Development, Sarrah Cannon Research Institute, USA*
- **Tania Estapé**, *Spain, Board member, Europa Uomo*

Q&A

End of day 1

DAY 2 – September 3rd, 2025.

09.00– 10.15: Innovation Without Access Is Failure – Delivering Genomic Equity in High-Tech Health Systems

Even in high-income countries, cutting-edge innovation often fails to reach the patients who need it most. Genomic medicine holds extraordinary promise—but its benefits remain unevenly distributed across geography, institution type, and tumor profile.

This session confronts the structural barriers that prevent equitable access to precision diagnostics and therapies, and outlines pragmatic solutions to close the implementation gap.

Key focus areas include:

- **Expanding access to molecular testing** in hospitals and community cancer centers
- **Reimbursing genomic tests** for patients with rare or currently untargetable mutations to avoid systemic exclusion
- **Accelerating access to tissue-agnostic therapies**, guided by the emerging convergence of ESMO, ASCO, and EMA frameworks
- **Designing inclusive systems** that ensure no patient is left behind due to postcode, trial design, or institutional capacity

This session aims to reframe access as a core pillar of innovation—not a downstream consideration—while proposing tangible pathways to achieve true genomic equity in high-tech health systems.

Moderator:

Setting the Scene:

- **Roberto Viola**, *Director-General of DG CONNECT, European Commission*
- **Roisin Adams**, *NCPE,Chair of the Health Technology Assessment Coordination Group*

Panel:

- **Benjamin Gannon**, Vice President Europe & Americas at Guardant Health
- **Zsuzsanna Devecseri**, *Global Head, Medical Affairs, Oncology, Novartis*
- **Tõnu Esko**, *Vice Rector, Professor and long-time senior management member at Estonian Biobank*

10.15 – 11.30 Data That Delivers – Building a Smarter, Sustainable Healthcare Data System

Precision oncology cannot thrive on data volume alone. To translate insights into outcomes, health systems must prioritize **data quality, interoperability**, and **long-term sustainability**. This session explores the foundational shifts needed to move from fragmented data silos to a fit-for-purpose ecosystem that truly supports clinical decision-making and innovation.

Two core enablers will be addressed:

- **From Collection to Curation**: Moving beyond passive data accumulation toward active, standards-driven curation—supported by robust quality metrics, metadata protocols, and certification frameworks (e.g., ISO 20387). The aim: real-world data that is reliable, comparable, and decision-ready.
- **Sustainable Business Models**: Developing financial models that balance public benefit with economic viability—such as tiered-access strategies, collaborative "data clubs," and hybrid public–private stewardship networks. The session will examine how these models can ensure continuous data generation, governance, and reuse.

Through real-world examples and actionable policy levers, this session will outline how the EU and other high-income systems can future-proof their oncology data infrastructure—supporting precision care at scale, sustainably.

Moderator: Antoni Moliner Monseratt, *Vice président - ALAN Vice President of the National Committee of the Rare Diseases Plan of Luxembourg*

Setting the Scene:

- **Falk Ehmann**, *Head of Innovation and Development Accelerator, European Medicine Agency*
- **Ciarán Nichol**, *European Commission Director Health & Food EC-Joint Research Centre*

Panel:

- **Marcis Leja,** *University of Latvia – Coordinator of EUCanScreen*
- **Joanne M. Hackett,** *Vice President Health System Services, IQVIA*
- **Etienne Richer**, *Director, Genomics Programs, Genome Canada*

EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

Q&A

11.30– 11.45 Break

11.45 – 13.00 Choose Europe, Back Health: Translating the Draghi Vision into Scaled Healthcare Innovation

The Draghi Report calls for a bold new EU industrial and investment strategy grounded in sovereignty, resilience, and cross-border scale. But what does this mean for healthcare? With growing innovation gaps between EU member states and global competitors, now is the time to embed health as a central pillar of Europe's industrial and strategic future.

This session explores how the **Choose Europe** narrative can be extended to healthcare: strengthening Europe's position as a global leader in biomedical innovation, digital health, and equitable access. It will unpack the policy tools, investment mechanisms, and regulatory shifts needed to turn the Draghi recommendations into actionable momentum—placing health not as a cost, but as a high-value strategic asset.

Key Themes:

- Aligning health innovation with Europe's industrial strategy and open strategic autonomy
- Leveraging EU cohesion and recovery funds to close East–West innovation divides
- Scaling Europe-led platforms in genomics, digital health, and AI
- Incentivizing industry to "Choose Europe" for trials, manufacturing, and innovation deployment
- Positioning health within broader security, resilience, and economic competitiveness agendas

Moderator:

Setting the Scene:

- **Luis Garicano,** *Professor of Public Policy, School of Public Policy, London School of Economics*
- **Vlad Vasile Voiculesc,** *MEP, European Parliament*

Panelists

- **Denis Lacombe**, *Executive Director, European Organisation for Research Treatemnt of Cancer*
- **Ruth Ladenstein**, *Pediatrics, Oncology Board Member of the Cancer Mission*
- **Stefania Boccia**, *Professor of Hygiene and Public Health at the Università Cattolica del Sacro Cuore (UCSC), Rome, Italy*
-

13.00– 14.00 Lunch

14.00– 15.15 Harmonizing Global Funding – Aligning National Strategies for Scaled Impact in High-Income Systems

As precision oncology and advanced diagnostics accelerate globally, the absence of coordinated investment and policy frameworks is creating fragmented progress. While high-income countries often lead in research, regulatory science, and infrastructure, their efforts remain siloed—limiting opportunities for collective scale, shared evidence generation, and global equity.

This session explores how **international alignment of national cancer strategies** can unlock smarter investments, faster access, and more inclusive research. By building transatlantic and multilateral bridges, countries can move beyond isolated excellence toward **globally coherent innovation pathways**.

Discussion will focus on:

- **Establishing joint Health Technology Assessment (HTA) frameworks** under the EU HTA Regulation and piloting mechanisms for transcontinental collaboration
- **Launching mutual recognition pilots between agencies like EMA, FDA, PMDA, and ANVISA** to accelerate the global approval of tumor-agnostic and biomarker-driven therapies
- **Dedicating 5% of national cancer budgets** to support multinational collaborative trials that generate real-world, generalizable evidence across geographies and populations
- **Creating globally aligned funding instruments** to de-risk innovation in low-access, high-need disease areas, especially in underserved regions of high-income countries and emerging economies

This session will offer a forward-looking blueprint for **harmonizing global regulatory and financial ecosystems**, ensuring that innovation can scale equitably—not just nationally, but internationally.

By harmonizing regulatory, financial, and trial infrastructure, this session will chart a pathway for scaling innovation through shared responsibility—and unlocking the full promise of global collaboration.

Moderator: Hadi Mohamad Abu Rasheed, *Head of Professional Development and Research, Qatar Cancer Society*

Panel:

- **Prof. Hesham Elghazaly, MD,** *Professor of Clinical Oncology, Head of Medical Research Center MASRI, Ain Shams University*
- **Prof. Adda Bounedjar, MD**, *Head of Oncology, Central Hospital of Algiers, Board Member, African Organization for Research and Training in Cancer (AORTIC)*

- **Hanadi Alouthah**, *CEO at Zahra Breast Cancer Association, Saudi Arabia***Stefania Boccia**, *Professor of Hygiene and Public Health at the Università Cattolica del Sacro Cuore (UCSC), Rome, Italy*

15.15– 16.00 Spotlight 3: – Ophthalmology & Diabetes: Unlocking the Potential of AI-Driven Prevention

Advances in AI are poised to transform early detection and chronic disease management in ophthalmology and diabetes—yet reimbursement and regulatory barriers continue to stall their adoption.

This session explores two high-impact opportunities where innovation is outpacing system readiness:

- **AI-driven diabetic retinopathy screening**, where algorithms show high clinical promise but face persistent reimbursement delays in countries like France
- **Continuous glucose monitoring integrated with AI**, which offers predictive insights for diabetes management but encounters cost-effectiveness challenges in health technology assessments, notably in Germany

The discussion will focus on how to overcome these hurdles, align incentives, and build the evidence needed to integrate AI tools into routine care—before preventable complications become irreversible burdens

Key Question: *Who pays for preventative digital tools?*

Moderator: **Delia Nicoară**, *Public Health and Management Specialist, Oncology Institute "Prof. Dr. Ion Chiricuță," Cluj-Napoca*

Setting the Scene:

- **Peter Schwarz** is President of the International Diabetes Federation.
- **Maria Walsh**, Group of the European People's Party, European

Panel:

16.00 – 17.15 Concluding Session: Toward a Technology-Driven Cancer Control Framework Designing a Blueprint for High-Income Systems in the Next Decade

This final session consolidates insights into a shared roadmap: a Technology-Driven Cancer Control Framework for HICs and the EU. Proposed components:

- **Core Diagnostic Infrastructure**
  - Universal access to NGS, MRD, and liquid biopsy
  - Publicly funded diagnostic bundles tied to treatment pathways

    - Federated EU-wide data standards and registries
- **Regulatory Innovation**
    - Adaptive approval pathways for diagnostics and digital tools
    - Real-world validation as part of EMA conditional approvals
    - National sandbox frameworks for experimental care models
- **Procurement and Reimbursement**
    - Equity-adjusted DRG models and risk-sharing contracts
    - Public-private diagnostic funding pools
    - EU joint procurement for diagnostic platforms
- **Governance**
    - National implementation accelerators modeled on Genomics England or Denmark's Cancer Registry
    - Inclusion of patient organizations and academic consortia in framework oversight
    - Shared performance indicators (e.g., time-to-molecular diagnosis, recurrence-free survival tracking)

The session will conclude with a draft Declaration for Precision Oncology Acceleration to be endorsed by policymakers, patient groups, industry, and multilateral actors—creating a shared implementation agenda for 2025–2030.

Moderator: Antoni Moliner Monseratt, *Vice président - ALAN Vice President of the National Committee of the Rare Diseases Plan of Luxembourg*

Panel

- **Vivek Subbiah, MD**, *Chief of Early-Phase Drug Development, Sarrah Cannon Research Institute, USA*
- **John Bell** *(Regius Professor of Medicine, Oxford; Genomics England*
- **David Novillo Ortiz,** *Unit Head and Regional Adviser, Data and Digital Health (WHO)*
- **Olivér Várhely,** *European Commissioner for Health and Animal Welfare*